Payment overview · 2025
General Payments
$399.53
21 reported records · 11 companies
Healthcare provider profile · identity verified
Christina Biester
Allopathic & Osteopathic Physicians|Family Medicine · CHESTERFIELD, SC · NPI 1891700506
Verified facts
What the public records show
CMS Open Payments records show Christina Biester received $399.53 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.41 | 19.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.95 | 18.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.04 | 12.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.63 | 11.4% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $36.10 | 9.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.61 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.39 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.95 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.67 | 4.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.59 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.19 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.53 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.95 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.95 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.44 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.04 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $36.10 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 178 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 143 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 213 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
143 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
162 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
213 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 88 |
| Gabapentin | Gabapentin | 264 | 82 |
| Furosemide | Furosemide | 258 | 87 |
| Prednisone | Prednisone | 258 | 121 |
| Omeprazole | Omeprazole | 239 | 74 |
| Losartan Potassium | Losartan Potassium | 221 | 56 |
| Ozempic | Semaglutide | 213 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 200 | 57 |
| Metformin Hcl | Metformin Hcl | 200 | 58 |
| Lisinopril | Lisinopril | 198 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 59 |
| Jardiance | Empagliflozin | 178 | 47 |
| Trulicity | Dulaglutide | 162 | 41 |
| Lovastatin | Lovastatin | 149 | 44 |
| Mirtazapine | Mirtazapine | 149 | 47 |
| Mounjaro | Tirzepatide | 143 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 35 |
| Meloxicam | Meloxicam | 129 | 57 |
| Azithromycin | Azithromycin | 128 | 84 |
| Fluconazole | Fluconazole | 126 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 37 |
| Eliquis | Apixaban | 103 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 50 |
| Spironolactone | Spironolactone | 100 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 24 |
| Carvedilol | Carvedilol | 94 | 27 |
| Simvastatin | Simvastatin | 91 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 30 |
| Alendronate Sodium | Alendronate Sodium | 83 | 25 |
| Allopurinol | Allopurinol | 82 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 23 |
| Trazodone Hcl | Trazodone Hcl | 80 | 27 |
| Clonazepam | Clonazepam | 78 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 17 |
| Potassium Chloride | Potassium Chloride | 72 | 21 |
| Alprazolam | Alprazolam | 70 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 54 |
| Montelukast Sodium | Montelukast Sodium | 67 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 16 |
| Tramadol Hcl | Tramadol Hcl | 63 | 18 |
| Sertraline Hcl | Sertraline Hcl | 62 | 23 |
| Amoxicillin | Amoxicillin | 61 | 50 |
| Memantine Hcl | Memantine Hcl | 57 | 13 |
| Repatha Syringe | Evolocumab | 57 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 42 |
| Famotidine | Famotidine | 54 | 13 |
| Baclofen | Baclofen | 49 | 19 |
| Ezetimibe | Ezetimibe | 49 | 14 |
| Xarelto | Rivaroxaban | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 48 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 20 |
| Nifedipine Er | Nifedipine | 45 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 40 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | 11 |
| Cephalexin | Cephalexin | 39 | 28 |
| Lactulose | Lactulose | 39 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | 11 |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Atenolol | Atenolol | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 11 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 12 |
| Nystatin | Nystatin | 28 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 17 |
| Temazepam | Temazepam | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | 15 |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Fluorouracil | Fluorouracil | 15 | 12 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.53 · 21 records | Novo Nordisk Inc | CAPLYTA, CLOTTRIEVER BOLD CATHETER, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, Korlym, MOUNJARO, NUPLAZID, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error